Increased ferroptosis of erythrocytes is associated with myelodysplastic syndromes

Area of Science:

• Hematology
• Cell Biology
• Oncology

Background:

• Anemia is a primary symptom of myelodysplastic syndromes (MDS).
• Programmed cell death of erythrocytes contributes to anemia in MDS.
• Ferroptosis, a newly identified iron-dependent cell death, is implicated.

Purpose of the Study:

• To investigate the association between anemia in MDS patients and ferroptosis in nucleated erythrocytes (NEs).
• To explore the role of ferroptosis in the pathogenesis of anemia in MDS.

Main Methods:

• Quantification of lipid peroxidation, Fe2+ levels, cell death rates, glutathione (GSH), and malondialdehyde (MDA) in bone marrow CD235a+ NEs from MDS patients.
• Evaluation of ferroptosis-related molecule expression (ACSL4, GPX4, SLC7A11) via qRT-PCR and Western Blotting.
• Inhibition of ferroptosis using Fer-1 to assess its impact on cell viability and ferroptosis indicators.

Main Results:

• Increased ferroptosis levels were observed in bone marrow NEs of MDS patients.
• Elevated ferroptosis in NEs correlated with anemia severity and iron overload.
• Fer-1 treatment demonstrated a reduction in ferroptosis and improved cell viability.

Conclusions:

• Ferroptosis is a significant contributor to anemia in myelodysplastic syndromes.
• Targeting ferroptosis may offer a therapeutic strategy for managing anemia in MDS patients.
• Further research is warranted to elucidate the precise mechanisms linking ferroptosis, iron metabolism, and MDS pathogenesis.